Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise-March 2024-www.financetom.com

Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise

May 16, 2024 10:18 AM

12:52 PM EDT, 05/16/2024 (MT Newswires) -- Oragenics ( OGEN ) said Thursday that it is preparing to start a phase 2 clinical trial for its potential intranasal treatment for concussion, ONP-002.

The company said it has secured an ample supply of intranasal devices in preparation for the trial.

Oragenics ( OGEN ) added that it has collaborated with Avance Clinical to facilitate the implementation of the phase 2a trial in emergency departments at level one trauma centers.

Oragenics ( OGEN ) shares were up 5.6% in recent trading.

Price: 1.73, Change: +0.09, Percent Change: +5.62

Previous page： From aloo paratha to chicken chettinad, Tata's Air India revamps in-flight menu Next page： Deltatech Gaming, Pristine Logistics get SEBI's go-ahead to float IPO

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

From aloo paratha to chicken chettinad, Tata's Air India revamps in-flight menu

Oct 3, 2022

The new Air India in-flight menu, featuring an assortment of gourmet meals, trendy appetizers, and decadent desserts, showcases India's locally sourced culinary influence.

Deltatech Gaming, Pristine Logistics get SEBI's go-ahead to float IPO

Oct 3, 2022

Deltatech Gaming Ltd and Pristine Logistics & Infraprojects Ltd have received SEBI's go-ahead to raise funds through an initial public offering (IPO). The two companies, which filed their preliminary IPO papers with SEBI during May and June, obtained their observation letter on September 30, an update with the markets watchdog showed on Monday.

Credit quality of companies strengthens in first half of FY23: Report

Oct 3, 2022

Upgrades saw an 18 percent increase in the agency's portfolio entities in H1 on an annualised basis, which in FY22 was a notch higher at 19 percent, making it a significant mark-up over the past five-year and 10-year average of 11 percent, the agency said.

Inside Out | Deep dive into Galaxy Surfactants and all about NMDC

Oct 3, 2022

CNBC-TV18's Sonal Bhutra spoke to U Shekhar, promoter and managing director at Galaxy Surfactants to understand this business, its supply chain, and also what will drive growth from here.